Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model

被引:10
|
作者
Crepey, Pascal [1 ]
Boiron, Louis [2 ]
Araujo, Rafael Rodrigo [2 ]
Lopez, Juan Guillermo [3 ]
Petitjean, Audrey [4 ]
de Albuquerque Luna, Expedito Jose [5 ]
机构
[1] Univ Rennes, Dept Quantitat Methods Publ Hlth, UPRES EA Reperes 7449, EHESP, 15 Av Prof, F-35043 Rennes, France
[2] Sanofi Pasteur, Av Nacoes Unidas,14410 Condominio Parque, BR-04794000 Sao Paulo, SP, Brazil
[3] Sanofi Pasteur, Av Univ 1738, Ciudad De Mexico 04000, Cdmx, Mexico
[4] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France
[5] Univ Sao Paulo, Inst Trop Med IMT, Av Dr Eneas Carvalho Aguiar,470 Jardim Amer, BR-05403000 Sao Paulo, SP, Brazil
关键词
QIV; Quadrivalent; Public health; Cost-effectiveness; Vaccine; Influenza; Brazil; PUBLIC-HEALTH IMPACT; SEASONAL INFLUENZA; BURDEN;
D O I
10.1186/s12889-020-09409-7
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Influenza epidemics significantly weight on the Brazilian healthcare system and its society. Public health authorities have progressively expanded recommendations for vaccination against influenza, particularly to the pediatric population. However, the potential mismatch between the trivalent influenza vaccine (TIV) strains and those circulating during the season remains an issue. Quadrivalent vaccines improves vaccines effectiveness by preventing any potential mismatch on influenza B lineages. Methods We evaluate the public health and economic benefits of the switch from TIV to QIV for the pediatric influenza recommendation (6mo-5yo) by using a dynamic epidemiological model able to consider the indirect impact of vaccination. Results of the epidemiological model are then imputed in a health-economic model adapted to the Brazilian context. We perform deterministic and probabilistic sensitivity analysis to account for both epidemiological and economical sources of uncertainty. Results Our results show that switching from TIV to QIV in the Brazilian pediatric population would prevent 406,600 symptomatic cases, 11,300 hospitalizations and almost 400 deaths by influenza season. This strategy would save 3400 life-years yearly for an incremental direct cost of R$169 million per year, down to R$86 million from a societal perspective. Incremental cost-effectiveness ratios for the switch would be R$49,700 per life-year saved and R$26,800 per quality-adjusted life-year gained from a public payer perspective, and even more cost-effective from a societal perspective. Our results are qualitatively similar in our sensitivity analysis. Conclusions Our analysis shows that switching from TIV to QIV to protect children aged 6mo to 5yo in the Brazilian influenza epidemiological context could have a strong public health impact and represent a cost-effective strategy from a public payer perspective, and a highly cost-effective one from a societal perspective.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model
    Pascal Crépey
    Louis Boiron
    Rafael Rodrigo Araujo
    Juan Guillermo Lopez
    Audrey Petitjean
    Expedito José de Albuquerque Luna
    [J]. BMC Public Health, 20
  • [2] Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
    Dominic Thorrington
    Edwin van Leeuwen
    Mary Ramsay
    Richard Pebody
    Marc Baguelin
    [J]. BMC Medicine, 15
  • [3] Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
    Thorrington, Dominic
    van Leeuwen, Edwin
    Ramsay, Mary
    Pebody, Richard
    Baguelin, Marc
    [J]. BMC MEDICINE, 2017, 15
  • [4] Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis
    Zhu, Dawei
    Lv, Min
    Bai, Yunhua
    Wu, Jiang
    He, Ping
    [J]. VACCINE, 2022, 40 (07) : 994 - 1000
  • [5] COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINES FOR CHILDREN
    Yang, M. C.
    Tan, C. H.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A161 - A161
  • [6] An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model
    Chit, Ayman
    Roiz, Julie
    Aballea, Samuel
    [J]. PLOS ONE, 2015, 10 (07):
  • [7] COST-EFFECTIVENESS ANALYSIS OF QUADRIVALENT INFLUENZA VACCINE IN SPAIN
    Garcia Rojas, A.
    Ortiz de Lejarazu, R. L.
    Reina, J.
    Callejo, D.
    Cuervo Uria, J.
    Morano Larragueta, R.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A588 - A588
  • [8] Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain
    Garcia, Amos
    Ortiz de Lejarazu, Raul
    Reina, Jordi
    Callejo, Daniel
    Cuervo, Jesus
    Morano Larragueta, Raul
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (09) : 2269 - 2277
  • [9] Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines
    Thommes, Edward W.
    Kruse, Morgan
    Kohli, Michele
    Sharma, Rohita
    Noorduyn, Stephen G.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (04) : 867 - 876
  • [10] Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
    Bianculli, Pablo Manuel
    Bellier, Lucile
    Mangado, Ignacio Olivera
    Perez, Carlos Grau
    Mieres, Gustavo
    Lazarov, Luis
    Petitjean, Audrey
    Dibarboure, Hugo
    Lopez, Juan Guillermo
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (05)